Yüklüyor......
Sunitinib in the treatment of metastatic renal cell carcinoma
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment option in the first-line treatment of metastatic renal cell cancer...
Kaydedildi:
| Yayımlandı: | Ther Adv Urol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5117167/ https://ncbi.nlm.nih.gov/pubmed/27904651 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287216663979 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|